

3 July 2024

## Treatment of Haemophilia Patients

1. In the last 3 months (April, May, June 2024), how many haemophilia A and B patients were treated with the following coagulation factors in your Trust and how much volume (IUs) was used.

	Number of treated patients	Volume used (IUs)
Hemlibra (non-inhibitor patients)		
Hemlibra (inhibitor patients)		
Advate		
Adynovi		
Elocta		
Esperoct		
NovoEight		
ReFacto AF		
Nuwiq		
Idelvion		
Refixia		
Alprolix		
BeneFIX		
Replenine		
Rixubis		

2. In the last 3 months (April, May, June 2024), how many von Willebrand patients were treated in your Trust with the following coagulation factors for the following regimen and how much volume (IUs) was used:

a. Voncento

	Number of treated patients	Volume used (IUs)
Prophylaxis		
Intermittent prophylaxis		
Surgeries		
Treatment of bleeds		

b. Veyvondi

	Number of treated patients	Volume used (IUs)
Prophylaxis		
Intermittent prophylaxis		
Surgeries		
Treatment of bleeds		

3 July 2024

c. Wilate

	Number of treated patients	Volume used (IUs)
Prophylaxis		
Intermittent prophylaxis		
Surgeries		
Treatment of bleeds		

d. Willfact

	Number of treated patients	Volume used (IUs)
Prophylaxis		
Intermittent prophylaxis		
Surgeries		
Treatment of bleeds		

The information requested above is exempt under Section 21: Information already reasonably accessible.

The information requested is readily available from the National Haemophilia Database (NHD).

We supply treatment in line with the National Framework and report all diagnosis, treatments and regimes on a quarterly basis to the National Haemophilia Database provided by the UKHCDO.

Any individual/company can apply to the National Haemophilia Database for this information.

[NHD – UKHCDO](#)